Abstract:This study aimed to assess the ability of different technology platforms to detect epidermal growth factor receptor (EGFR) mutations including L858R, E19-dels, T790M, and G719X from circulating tumor DNA (ctDNA) in patients with non-small cell lung cancer (NSCLC). Plasma samples were collected from 20 patients with NSCLC including detailed clinical information along with data regarding treatment response. ctDNA was extracted from 10 mL plasma using the QIAamp Circulating Nucleic Acid Kit (Qiagen). Extracted ctDNA was analyzed using two real time-amplification refractory mutation system-quantitative PCR platforms (cobas® EGFR Mutation Test: cobas; and AmoyDx® EGFR 29 Mutations Detection Kit: ADx), one digital platform (Droplet DigitalTM PCR, ddPCR: Bio-rad), and one next-generation sequencing platform (firefly NGS: Accuragen). If a positive result was obtained from any one of the four platforms, the sample was categorized as positive. We identified 15 EGFR mutations in 20 patients with NSCLC using the four platforms, for which 7, 11, 10, and 12 mutations were detected by ADx, cobas, ddPCR, and firefly NGS, respectively. Among the 15 EGFR mutations, six and seven EGFR alterations demonstrated an allele frequency of more or less than 1% (group A or B, respectively), and two exhibited unknown allele frequency. In group A, 5, 5, 5, and 6 EGFR mutations were detected by ADx ,cobas, ddPCR, and firefly NGS, respectively. The positive coincidence rate of any two platforms ranged from 66.7% to 100% and the kappa value varied from 0.787 to 1.000 in group A. In group B, 1, 5, 5, and 6 EGFR mutations were detected and the positive coincidence rate of any two platforms ranged from 16.7% to 100% and the kappa value varied from 0.270 to 1.000. The output of cobas, ddPCR, and firefly NGS were highly correlated, whereas ADx displayed weak concordance with these three platforms in group B. In addition, we identified 75 wild-type loci when EGFR alleles identified as negative by one or more platforms were considered as negative. ADx, cobas, ddPCR, and firefly NGS uncovered 73, 69, 70, and 68 EGFR wild-type loci, respectively. The concordance and negative coincidence rates between any two platforms were over 90%. The detection rate and concordance were probably affected by the abundance of EGFR mutations and the sensitivity of different platforms. Three platforms, including cobas, ddPCR, and firefly NGS, exhibited higher positive coincidence and detection rates when the allele frequency was lower than 1%.

Assessment of the Clinical Application of Detecting EGFR, KRAS, PIK3CA and BRAF Mutations in Patients with Non-Small Cell Lung Cancer Using Next-Generation Sequencing

Clinical significance of multi-sample next-generation sequencing for detection of gene mutations in non-small cell lung cancer

Molecular Characterization and Prognostic Analysis of Non-Small Cell Lung Cancer: A Single Centric Real-World Study.

Validating a Targeted Next-Generation Sequencing Assay and Profiling Somatic Variants in Chinese Non-Small Cell Lung Cancer Patients

Comparison of Next-Generation Sequencing and Immunohistochemistry Analysis for Targeted Therapy-Related Genomic Status in Lung Cancer Patients.

Comprehensive Analysis of NGS and ARMS-PCR for Detecting EGFR Mutations Based on 4467 Cases of NSCLC Patients

The Advantage of Targeted Next-Generation Sequencing over qPCR in Testing for Druggable EGFR Variants in Non-Small-Cell Lung Cancer

Application of Next Generation Sequencing in Pleural Effusion Molecular Profiling Using Oncomine™ Lung Cell-Free Total Nucleic Acid Research Assay.

The Landscape of Actionable Genomic Alterations by Next-Generation Sequencing in Tumor Tissue Versus Circulating Tumor DNA in Chinese Patients With Non-Small Cell Lung Cancer

Utility of Circulating Tumor DNA Assay in Identifying Mutations and Guiding Matched Targeted Therapy in Lung Cancers

High Sensitive and Non-invasive Ctdnas Sequencing Facilitate Clinical Diagnosis and Clinical Guidance of Non-small Cell Lung Cancer Patient: A Time Course Study

Next-generation sequencing as a valuable tool for mutational spectrum in advanced-stage NSCLC patients

Performance Validation of an Amplicon-Based Targeted Next-Generation Sequencing Assay and Mutation Profiling of 648 Chinese Colorectal Cancer Patients.

Analytical and clinical validation of a NGS panel in detecting targetable variants from ctDNA of metastatic NSCLC patients

Detection of Plasma EGFR Mutations in NSCLC Patients with a Validated ddPCR Lung cfDNA Assay

Targeted Next-Generation Sequencing of 491 Lung Cancers in Clinical Practice: Implications for Future Detection Strategy and Targeted Therapy

P3.02b-011 Comparison of Four Leading Technologies for Detecting EGFR Mutations in Circulating Tumor DNA from Patients with Non-Small Cell Lung Carcinoma

Utilizing Plasma-Based Next-Generation Sequencing to Expedite the Diagnostic Process in Suspected Lung Cancer: A Case Report

Development and Analytical Validation of a Targeted Next-Generation Sequencing Panel to Detect Actionable Mutations for Targeted Therapy

Next-Generation Sequencing for Genotyping of Endobronchial Ultrasound- Guided Transbronchial Needle Aspiration Samples in Lung Cancer

Detection of EGFR, KRAS, BRAF, EML4-ALK fusion genes by ARMS and NGS in patients with non-small cell lung cancer